A feasibility investigation of mindfulness-based cognitive therapy for people with Huntington’s disease

Eccles, Fiona J. R.; Craufurd, David; Smith, Alistair; Davies, Rhys; Glenny, Kristian; Homberger, Max; Peeren, Siofra; Rogers, Dawn; Rose, Leona; Skitt, Zara; Theed, Rachael; Simpson, Jane

doi:10.1186/s40814-020-00631-z

Pilot and Feasibility Studies

Table 3 Positive affect, coping, sleep and quality of life

From: A feasibility investigation of mindfulness-based cognitive therapy for people with Huntington’s disease

	Pre		Post				3 months post				1 year post
	M	SD	M	SD	r	r (CI)	M	SD	r	r (CI)	M	SD	r	r (CI)
PANAS-P	29.2	9.0	31.9	10.2	−0.11	−0.69, 0.56	30.5	6.9	0.16	−0.49, 0.69	32.2	8.1	0.35	−0.32, 0.78
COPE
Self-distraction	5.50	1.89	4.91	2.17	−0.28	−0.75, 0.38	4.55	2.02	−0.39	-0.80, 0.28	4.64	2.16	−0.38	−0.80, 0.28
Active coping	5.25	1.66	5.73	2.00	0.42	−0.24, 0.81	5.64	1.86	0.13	−0.51, 0.68	6.00	1.90	0.30	−0.37, 0.76
Denial	3.58	1.93	2.73	1.19	−0.52	−0.85, 0.12	2.64	1.50	−0.51	−0.85, 0.12	2.45	0.94	−0.60	-−0.88, 0.00
Substance use	3.17	2.12	3.27	2.05	0.00	−0.60, 0.60	3.64	1.91	0.39	−0.27, 0.80	3.45	2.16	0.30	−0.36, 0.76
Emotional support	4.67	2.39	5.27	1.85	0.39	−0.28, 0.80	5.00	2.28	0.11	−0.53, 0.66	5.55	1.81	0.34	−0.33, 0.78
Instrumental support	4.58	2.23	4.82	1.89	0.26	−0.40, 0.74	3.91	1.81	−0.56	−0.87, 0.06	5.09	1.64	0.16	−0.48, 0.70
Behavioural disengagement	4.00	1.60	3.18	1.89	−0.53	−0.86, 0.10	2.55	1.04	−0.64	−0.90, −0.07	2.82	1.17	−0.60	−0.88, 0.00
Venting	4.50	1.93	3.90	1.45	−0.55	−0.86, 0.08	4.00	1.34	−0.16	−0.70, 0.48	3.91	1.70	−0.26	−0.74, 0.40
Positive reframe	4.83	1.53	5.55	1.92	0.44	−0.21, 0.82	5.36	1.69	0.28	−0.39, 0.75	6.27*	1.62	0.61	0.01, 0.89
Planning	4.83	1.90	5.45	2.34	0.47	−0.18, 0.83	4.73	1.90	−0.08	−0.65, 0.55	4.91	2.02	0.00	−0.60, 0.60
Humour	4.92	2.19	5.00	2.37	0.16	−0.49, 0.69	4.55	2.02	−0.26	−0.74, 0.40	4.73	2.24	−0.20	−0.71, 0.46
Acceptance	6.75	1.42	6.27	2.01	−0.24	−0.73, 0.42	5.82	1.47	−0.57	−0.87, 0.05	6.64	2.16	−0.06	−0.63, 0.56
Religion	3.67	2.42	4.91	2.26	0.74	0.26, 0.93	4.36	2.11	0.46	−0.19, 0.83	4.73	2.69	0.67	0.12, 0.91
Self-blame	4.42	1.56	3.91	1.51	−0.28	−0.75, 0.39	3.82	1.83	−0.26	−0.74, 0.41	3.18	1.32	−0.47	−0.83, 0.18
PSQI Total score	8.42	4.66	7.82	4.47	−0.28	−0.75, 0.39	6.36	3.70	−0.34	−0.78, 0.33	6.50	3.78	−0.36	−0.81, 0.35
WHOQOL
Physical	61.1	25.1	64.3	28.1	−0.07	−0.70, 0.62	65.6	22.5	0.00	−0.70, 0.70	64.3	28.3	−0.18	−0.79, 0.60
Psychological	52.7	26.8	60.7	24.3	0.28	−0.47, 0.80	52.6	25.0	−0.24	−0.81, 0.56	56.5	17.6	0.00	−0.70, 0.70
Social	61.1	26.4	67.7	36.0	0.23	−0.52, 0.77	58.3	32.1	−0.40	−0.86, 0.42	62.5	31.2	0.00	−0.70, 0.70
Environmental	70.1	17.9	69.1	21.5	−0.03	−0.68, 0.65	67.2	23.8	−0.42	−0.87, 0.41	66.0	19.8	−0.48	−0.89, 0.34

Pre n = 12 (except WHOQOL n = 9); post n = 11 (except PANAS-P n = 10; WHOQOL n = 8); 3-months n = 11 (except WHOQOL n = 8); 1-year n = 11 (except PSQI n = 10; WHOQOL n = 8)
PANAS-P positive subscale of the positive and negative affect scale. PSQI Pittsburgh Sleep Quality Index WHOQOL brief version of the World Health Organisation Quality of Life Instrument. r is effect size (r = Z/√ (N), where Z is the standardised test statistic from a Wilcoxon signed-rank test and N is the sample size. r (CI) is 95% confidence interval for r. A positive r indicates an increase in positive affect on the PANAS-P, an increase in quality of life on the WHOQOL and an increase in use of each coping strategy on the COPE. A negative r indicates improvement in sleep on the PSQI

Back to article page

ISSN: 2055-5784

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com